Rheumatoid Arthritis and its new drugs
Rheumatoid joint pain is a long haul, immune system malady that causes joint growing (aggravation), torment, redness, warmth, and firmness. The wrists, fingers, knees, feet, and lower legs are most ordinarily included. The reason for rheumatoid joint inflammation isn't known. Rheumatoid joint inflammation for the most part influences joints on the two sides of the body similarly, and grows gradually after some time. It can likewise influence different organs in the body. Beginning treatment at analysis can assist with constraining changeless joint devastation.
About 1%, or 1 out of every 100 individuals, has rheumatoid arthritis. It can occur at any age but it is usually seen in people between 25 and 55 years of age. Three times more women are affected than men
. The newest drugs for the treatment of rheumatoid arthritis are the Janus kinase (JAK) inhibitors, which are FDA approved under the brand names Rinvoq, Olumiant, and Xeljanz. Janus kinase (JAK) inhibitors work by blocking the activity of one or more of the Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of the pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis. Janus kinase (JAK) inhibitors are part of a wider group of drugs called DMARDs (Disease-Modifying Anti-Rheumatic Drugs). DMARDs work to slow the progression of joint damage in rheumatoid arthritis.